Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33055
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHurst L.A.en
dc.contributor.authorAtkins R.C.en
dc.contributor.authorChadban S.J.en
dc.contributor.authorNikolic-Paterson D.J.en
dc.contributor.authorRobertson T.E.en
dc.date.accessioned2021-05-14T11:12:29Zen
dc.date.available2021-05-14T11:12:29Zen
dc.date.copyright2002en
dc.date.created20021119en
dc.date.issued2012-10-18en
dc.identifier.citationClinical and Experimental Immunology. 130 (2) (pp 241-244), 2002. Date of Publication: 2002.en
dc.identifier.issn0009-9104en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/33055en
dc.description.abstractInterleukin-10 (IL-10) is a mesangial cell growth factor in vivo and in vitro. However, the mechanism by which IL-10 exerts its mitogenic activity is not known. The aim of this study was to determine whether IL-10 induces mesangial cell proliferation in a PDGF-dependent or independent fashion. A well-characterized rat mesangial cell line (1097) was used in a series of cell proliferation experiments in which cells were serum-starved and then incubated with recombinant IL-10 in the presence or absence of STI 571 (a specific inhibitor of signalling via the PDGF-alpha and beta receptors) or a neutralizing anti-PDGF-AB antibody. IL-10 induced significant mesangial cell proliferation at 24 and 48 h after cytokine addition. This response was inhibited totally by the addition of STI-571, demonstrating that IL-10 mitogenic activity has an absolute requirement for signalling through the PDGF receptor. In further studies, it was found that STI-571 could be added 24 h after IL-10 stimulation and still exert a profound inhibition of IL-10 mitogenic activity. The ability of a neutralizing anti-PDGF-AB antibody to inhibit completely IL-10-induced mesangial cell proliferation confirmed that IL-10 acts via induction of an autocrine PDGF response rather than the possibility that IL-10 may transactivate the PDGF receptor in a PDGF-independent fashion. In conclusion, this study has demonstrated that IL-10 induces mesangial cell proliferation via an autocrine PDGF-mediated mechanism. Thus, therapies which antagonize PDGF signalling will also inhibit any contribution of IL-10 to mesangial proliferation.en
dc.languageenen
dc.languageEnglishen
dc.publisherBlackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)en
dc.titleIL-10 induces mesangial cell proliferation via a PDGF-dependent mechanism.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1365-2249.2002.01975.xen
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid12390311 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12390311]en
dc.identifier.source35286210en
dc.identifier.institution(Robertson, Nikolic-Paterson, Hurst, Atkins, Chadban) Department of Nephrology, Monash Medical Centre, Clayton, Vic., Australia (Nikolic-Paterson, Atkins, Chadban) Monash University, Department of Medicine, Monash Medical Centre, Clayton, Vic., Australia (Chadban) Renal Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australiaen
dc.description.addressS.J. Chadban, Renal Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia. E-mail: steve.chadban@email.cs.nsw.gov.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsInterleukin-10 Mesangial PDGF Proliferation STI-571en
dc.identifier.authoremailChadban S.J.; steve.chadban@email.cs.nsw.gov.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptNephrology-
Appears in Collections:Articles
Show simple item record

Page view(s)

4
checked on Sep 16, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.